Family tips & talk



UTMB and NIH Researchers develop aerosolized vaccine that protects primates against Ebola







GALVESTON, Texas A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola. The findings were recently published in the Journal of Clinical Investigation. Previous studies with primates suggest that aerosols of most biothreat agents, which are particles dispersed in the air, are infectious. Recent studies show that contact with the Ebola virus through the mucus membranes that line the respiratory tract results in infection, suggesting that airway linings may be important portals of entry for the virus. Aerosolized delivery has never before been tested for an Ebola vaccine or any other viral hemorrhagic fever vaccine. A needle-free, inhalable vaccine against Ebola presents certain advantages, said lead author Michelle Meyer, UTMB postdoctoral fellow in the department of pathology. Immunization will not require trained medical personnel. The study characterized the immune responses generated by vaccination against Ebola delivered to the respiratory tract as either an aerosol or liquid. Direct comparisons were made with an unrelated protective injectable Ebola vaccine. This included detailed comparisons between immune T cell responses in the lungs, spleen and blood. A single vaccination with the aerosol developed by the researchers protected non-human primates against the severe disease and death caused by lethal Ebola infection. This study demonstrates successful aerosol vaccination against a viral hemorrhagic fever for the first time, said virologist Alex Bukreyev, UTMB professor and a senior author. A single-dose aerosol vaccine would enable both prevention and containment of Ebola infections, in a natural outbreak setting where healthcare infrastructure is lacking or during bioterrorism and biological warfare scenarios. The findings of this study provide the basis for advancing this experimental vaccine to an NIH phase I clinical study. Pending approval through an Investigative New Drug Application, the aerosolized form of the vaccine will be evaluated for replication, safety and immunity development in a study in adults. Other authors of this paper include UTMBs Tania Garron, Ndongala Lubaki, Chad Mire, Karla Fenton, Curtis Klages and Thomas Geisbert as well as Gene Olinger from the United States Army Institute for Infectious Diseases and Peter Collins from the National Institutes of Health. This study was supported by the National Institutes of Health. Photo Credit: Medici con l’Africa Cuamm. Creative Commons BY-SA (Cropped) https://www.flickr.com/photos/mediciconlafrica/15570753778/ https://creativecommons.org/licenses/by-sa/2.0/

Leave a Comment
Comments
  1. Realiza já
  2. Gertrude
  3. michael kors canada
  4. Danon Jewellery UK
  5. dallas seo experts
  6. Salvador
  7. Skin Youth
  8. coque iphone 5
  9. Sammie
  10. Garry
  11. home business operators
  12. Free download mp3 online
  13. www.grandsolarinc.com
  14. obtain 5000 facebook likes
  15. clash of clans hakc
  16. Home Job Placement
  17. butik tas wanita di batam
  18. us immigration
  19. Lasonya
  20. fashion choices
  21. Louisa
  22. schloss konflikt hacksaw
  23. replica michael kors
  24. Kaylene
  25. clash of clans hack ios 6.1.2
  26. Lane
  27. Bridget
  28. Vernita
  29. types of cigar wrappers
  30. linklicious discount
  31. Cleo
  32. Lela
  33. Micheal
  34. Arlette
  35. tire recycling to oil supplier
  36. jewellery yellowstone
  37. Marc
  38. dallas seo firm

Leave a Reply

Or